HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.

By PharmaVoice · Apr 28, 2026 · via PharmaVoice
Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
dealsformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly Spends Up to $3.8B on Three Vaccine Developers
DealsBriefing
Lilly Spends Up to $3.8B on Three Vaccine Developers
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
May 26, 2026
Medtronic inks $650M deal for SPR Therapeutics
DealsFierceBiotech ↗
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
May 24, 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
DealsPharmaceutical Technology ↗
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
May 22, 2026